These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18810326)

  • 1. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.
    Saraswathy S; Crawford FW; Lamborn KR; Pirzkall A; Chang S; Cha S; Nelson SJ
    J Neurooncol; 2009 Jan; 91(1):69-81. PubMed ID: 18810326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
    Nelson SJ; Kadambi AK; Park I; Li Y; Crane J; Olson M; Molinaro A; Roy R; Butowski N; Cha S; Chang S
    Neuro Oncol; 2017 Mar; 19(3):430-439. PubMed ID: 27576874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.
    Oh J; Henry RG; Pirzkall A; Lu Y; Li X; Catalaa I; Chang S; Dillon WP; Nelson SJ
    J Magn Reson Imaging; 2004 May; 19(5):546-54. PubMed ID: 15112303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.
    Crawford FW; Khayal IS; McGue C; Saraswathy S; Pirzkall A; Cha S; Lamborn KR; Chang SM; Berger MS; Nelson SJ
    J Neurooncol; 2009 Feb; 91(3):337-51. PubMed ID: 19009235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.
    Li X; Jin H; Lu Y; Oh J; Chang S; Nelson SJ
    NMR Biomed; 2004 Feb; 17(1):10-20. PubMed ID: 15011246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
    Nelson SJ; Li Y; Lupo JM; Olson M; Crane JC; Molinaro A; Roy R; Clarke J; Butowski N; Prados M; Cha S; Chang SM
    J Neurooncol; 2016 Oct; 130(1):171-179. PubMed ID: 27535746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.
    Park I; Tamai G; Lee MC; Chuang CF; Chang SM; Berger MS; Nelson SJ; Pirzkall A
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):381-9. PubMed ID: 17513061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
    Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.
    Li Y; Lupo JM; Polley MY; Crane JC; Bian W; Cha S; Chang S; Nelson SJ
    Neuro Oncol; 2011 May; 13(5):546-57. PubMed ID: 21297128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
    Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
    J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.
    Li Y; Lupo JM; Parvataneni R; Lamborn KR; Cha S; Chang SM; Nelson SJ
    Neuro Oncol; 2013 May; 15(5):607-17. PubMed ID: 23393206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
    Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU
    Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
    Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
    Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.
    Pirzkall A; McGue C; Saraswathy S; Cha S; Liu R; Vandenberg S; Lamborn KR; Berger MS; Chang SM; Nelson SJ
    Neuro Oncol; 2009 Dec; 11(6):842-52. PubMed ID: 19229057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.
    Jain R; Poisson L; Narang J; Gutman D; Scarpace L; Hwang SN; Holder C; Wintermark M; Colen RR; Kirby J; Freymann J; Brat DJ; Jaffe C; Mikkelsen T
    Radiology; 2013 Apr; 267(1):212-20. PubMed ID: 23238158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
    Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
    J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
    Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
    Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.